Vycor Medical, Inc. (OTCMKTS:VYCO) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
| Results of Operations and Financial Conditions | |
| Item 9.01 | Financial Statements and Exhibits |
Item 2.02. Results of Operations and Financial
Conditions
The information in this report and the exhibit attached hereto
are being furnished to Item 2.02 of Form 8-K and shall not be
deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, nor shall they be deemed incorporated by
reference in any filing with the Securities and Exchange
Commission under the Securities Act of 1934 or the Securities Act
of 1933, except as shall be expressly set forth by specific
reference to such filing.
On March 31, 2017, we issued a press release regarding our
financial results for the year ended December 31, 2016. A copy of
the press release is furnished as Exhibit 99.1 to this Form 8-K.
Non-GAAP Measures
We make reference to non-GAAP financial information in this press
release together with a reconciliation of these non-GAAP
financial measures to the comparable GAAP financial measures.
Specifically, we have provided non-GAAP Cash Operating Expenses
and non-GAAP Cash Operating Loss measures that exclude
Depreciation, Amortization and non-cash Stock Compensation.
We believe that these non-GAAP financial measures provide
investors with insight into what is used by management to conduct
a more meaningful and consistent comparison of our ongoing
operating results and trends, compared with historical results.
This presentation is also consistent with the measures management
uses to measure the performance of ongoing operating results
against prior periods and against our internally developed
targets. There are limitations in using these non-GAAP financial
measures because they are not prepared in accordance with GAAP
and may be different from non-GAAP financial measures used by
other companies. These non-GAAP financial measures should not be
considered in isolation or as a substitute for GAAP financial
measures. Investors and potential investors should consider
non-GAAP financial measures only in conjunction with the Companys
consolidated financial statements prepared in accordance with
GAAP and the reconciliation of non-GAAP financial measures in
this press release.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
Exhibit 99.1. Vycor Medical, Inc. Press Release dated March 31,
2017.
About Vycor Medical, Inc. (OTCMKTS:VYCO)
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company operates through two segments: Vycor Medical, which focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals, and NovaVision, which focuses on neuro-stimulation therapies and diagnostic devices for the treatment and screening of vision field loss resulting from neurological damage. The Company designs, develops and markets neurological medical devices and therapies. The Company operates in the United States and Europe. Vycor Medical’s product Vycor Medical’s ViewSite Brain Access System (VBAS) is a next generation retraction and access system. VBAS is a disposable product that can be used with microscopic, endoscopic and neuro-navigation systems. NovaVision has a family of therapies that both restore and compensate for lost vision. NovaVision’s products include VRT and Neuro-Eye Therapy (NeET), NeuroEyeCoach and Vision Diagnostic (VIDIT). Vycor Medical, Inc. (OTCMKTS:VYCO) Recent Trading Information
Vycor Medical, Inc. (OTCMKTS:VYCO) closed its last trading session 00.000 at 0.200 with 400 shares trading hands.